Advertisement

Osteoporosis International

, Volume 24, Issue 1, pp 121–137 | Cite as

Relationship between use of antidepressants and risk of fractures: a meta-analysis

  • V. RabendaEmail author
  • D. Nicolet
  • C. Beaudart
  • O. Bruyère
  • J.-Y. Reginster
Original Article

Abstract

Summary

It has been shown that antidepressants would have a direct action on bone metabolism and would be associated with increased fracture risk. Results from this large meta-analysis show that both SSRIs and TCAs are associated with a moderate and clinically significant increase in the risk of fractures of all types.

Introduction

This study seeks to investigate the relationship between use of antidepressants and the risk of fracture.

Methods

An exhaustive systematic research of case–control and cohort studies published or performed between 1966 and April 2011 that reported risk estimates of fracture associated with use of antidepressants was performed using MEDLINE, PsycINFO, and the Cochrane Systematic Review Database, manual review of the literature, and congressional abstracts. Inclusion, quality scoring, and data abstraction were performed systematically by three independent reviewers.

Results

A total of 34 studies (n = 1,217,464 individuals) were identified. Compared with non-users, the random effects pooled RR of fractures of all types, among antidepressant users, were 1.39 (95%CI 1.32–1.47). Use of antidepressants were associated with a 42 %, 47 %, and 38 % risk increase in non-vertebral, hip, and spine fractures, respectively ([For non-vertebral fractures: RR = 1.42, 95%CI 1.34–1.51]; [For hip fractures: RR = 1.47, 95%CI 1.36–1.58]; [For spine fractures: RR = 1.38, 95%CI 1.19–1.61]). Studies examining SSRI use showed systematically a higher increase in the risk of fractures of all types, non-vertebral, and hip fractures than studies evaluating TCA use.

Conclusions

Results from this large meta-analysis show that both SSRIs and TCAs are associated with a moderate and clinically significant increase in the risk of fractures of all types.

Keywords

Antidepressants Fractures Meta-analysis Selective serotonin-reuptake inhibitor Tricyclic antidepressants 

Notes

Acknowledgements

The authors acknowledge the support by a research grant from the Leon Fredericq Foundation of the Faculty of Medicine of the University of Liège.

Role of funding

The funders played no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Conflicts of interest

V. Rabenda received research grants from Servier and Nycomed. O. Bruyère received research grants from GlaxoSmithKline, IBSA, Merck Sharp & Dohme, Theramex, Novartis, Pfizer, Rottapharm, and Servier; consulting or lecture fees from IBSA, Rottapharm, and Servier; reimbursement for attending meetings from IBSA, Merck Sharp & Dohme, Novartis, Pfizer, Rottapharm, Theramex, and Servier. JY Reginster has received consulting fees or paid advisory boards from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex; lecture fees when speaking at the invitation of a commercial sponsor from Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk; grant support from Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Eli Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier.

References

  1. 1.
    Hayes D (2004) Recent developments in antidepressant therapy in special populations. Am J Manag Care 10(suppl l):S179–S185PubMedGoogle Scholar
  2. 2.
    Rabheru K (2004) Special issues in the management of depression in older patients. Can J Psychiatry 49(suppl1):41S–50SPubMedGoogle Scholar
  3. 3.
    Emslie G, Judge R (2000) Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr Scand Suppl 403:26–34PubMedCrossRefGoogle Scholar
  4. 4.
    Ray WA (1992) Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol 12:386–396PubMedGoogle Scholar
  5. 5.
    Thapa PB, Gideon P, Cost TW et al (1998) Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339:875–882PubMedCrossRefGoogle Scholar
  6. 6.
    Ruthazer R, Lipsitz LA (1993) Antidepressants and falls among elderly people in long-term care. Am J Public Health 83:746–749PubMedCrossRefGoogle Scholar
  7. 7.
    Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960PubMedCrossRefGoogle Scholar
  8. 8.
    Bloch F, Thibaud M, Dugué B, Brèque C, Rigaud AS, Kemoun G (2011) Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 2:329–346CrossRefGoogle Scholar
  9. 9.
    Warden SJ, Robling AG, Haney EM, Turner CH, Bliziotes MM (2010) The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 46:4–12PubMedCrossRefGoogle Scholar
  10. 10.
    Haney EM, Warden SJ (2008) Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact 8:133–145PubMedGoogle Scholar
  11. 11.
    Tsapakis EM, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E (2011) The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry. doi: 10.1016/j.eurpsy.2010.10.006
  12. 12.
    Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE (2007) Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167:1240–1245PubMedCrossRefGoogle Scholar
  13. 13.
    Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA (2008) Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 23:84–87PubMedCrossRefGoogle Scholar
  14. 14.
    Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM, Osteoporotic Fractures in Men Study Group (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167:1246–1251PubMedCrossRefGoogle Scholar
  15. 15.
    Ginzburg R, Rosero E (2009) Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann Pharmacother 43:98–103PubMedCrossRefGoogle Scholar
  16. 16.
    Schwan S, Hallberg P (2009) SSRIs, bone mineral density, and risk of fractures—a review. Eur Neuropsychopharmacol 19:683–692PubMedCrossRefGoogle Scholar
  17. 17.
    Haney EM, Warden SJ, Bliziotes MM (2010) Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46:13–17PubMedCrossRefGoogle Scholar
  18. 18.
    Takkouche B, Montes-Martínez A, Gill SS, Etminan M (2007) Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 30:171–184PubMedCrossRefGoogle Scholar
  19. 19.
    Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34PubMedCrossRefGoogle Scholar
  20. 20.
    Wells GA, Shea B, O’Connell D, Petersen J, Welch V, Losos M, Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa, Canada; http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
  21. 21.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRefGoogle Scholar
  22. 22.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple graphical test. BMJ 315:629–634PubMedCrossRefGoogle Scholar
  23. 23.
    Orwin R (1983) A fail-safe N for effect size in meta-analysis. J Educ Stat 8:157–159CrossRefGoogle Scholar
  24. 24.
    Rosenthal R (1979) The ‘file drawer problem’ and tolerance for null results. Psychol Bull 86:638–641CrossRefGoogle Scholar
  25. 25.
    Hatal R, Keitz S, Wyer P, Guyatt G, Evidence-Based Medicine Teaching Tips Working Group (2005) Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 172:661–665CrossRefGoogle Scholar
  26. 26.
    Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ 3rd (1987) Psychotropic drug use and the risk of hip fracture. N Engl J Med 316:363–369PubMedCrossRefGoogle Scholar
  27. 27.
    Jensen J, Nielsen LH, Lyhne N, Hallas J, Brøsen K, Gram LF (1991) Drugs and femoral neck fracture: a case–control study. J Intern Med 229:29–33PubMedCrossRefGoogle Scholar
  28. 28.
    Ray WA, Griffin MR, Malcolm E (1991) Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 151:754–756PubMedCrossRefGoogle Scholar
  29. 29.
    Cumming RG, Klineberg RJ (1993) Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 158:414–417PubMedGoogle Scholar
  30. 30.
    Lichtenstein MJ, Griffin MR, Cornell JE, Malcolm E, Ray WA (1994) Risk factors for hip fractures occurring in the hospital. Am J Epidemiol 140:830–838PubMedGoogle Scholar
  31. 31.
    Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F, Stergachis A (1996) Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 49:115–119PubMedCrossRefGoogle Scholar
  32. 32.
    Gambassi G, Lapane KL, Sgadari A, Bernabei R (1998) Elderly patients, use of antidepressants, and hip fracture. Lancet 352(9125):400, author reply 401–2PubMedCrossRefGoogle Scholar
  33. 33.
    Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N (1998) Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351(9112):1303–1307PubMedCrossRefGoogle Scholar
  34. 34.
    Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J (2001) Zolpidem use and hip fractures in older people. J Am Geriatr Soc 49:1685–1690PubMedCrossRefGoogle Scholar
  35. 35.
    Partanen J, Heikkinen J, Jämsä T, Jalovaara P (2002) Characteristics of lifetime factors, bone metabolism, and bone mineral density in patients with hip fracture. J Bone Miner Metab 20:367–375PubMedCrossRefGoogle Scholar
  36. 36.
    Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A (2003) Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 158:77–84PubMedCrossRefGoogle Scholar
  37. 37.
    Kaye JA, Jick H (2004) Epidemiology of lower limb fractures in general practice in the United Kingdom. Inj Prev 10:368–374PubMedCrossRefGoogle Scholar
  38. 38.
    French DD, Campbell R, Spehar A, Cunningham F, Foulis P (2005) Outpatient medications and hip fractures in the US: a national veterans study. Drugs Aging 22:877–885PubMedCrossRefGoogle Scholar
  39. 39.
    Hugenholtz GW, Heerdink ER, van Staa TP, Nolen WA, Egberts AC (2005) Risk of hip/femur in patients using antipsychotics. Bone 37:864–870PubMedCrossRefGoogle Scholar
  40. 40.
    Vestergaard P, Rejnmark L, Mosekilde L (2005) Reduced relative risk of fractures among users of lithium. Calcif Tissue Int 77:1–8PubMedCrossRefGoogle Scholar
  41. 41.
    Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17:807–816PubMedCrossRefGoogle Scholar
  42. 42.
    Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD (2008) Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 28:384–391PubMedCrossRefGoogle Scholar
  43. 43.
    Perreault S, Dragomir A, Blais L, Moride Y, Rossignol M, Ste-Marie LG, Fernandès JC (2008) Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Pharmacoepidemiol Drug Saf 17:248–259PubMedCrossRefGoogle Scholar
  44. 44.
    Abrahamsen B, Brixen K (2009) Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk. Osteoporos Int 20:585–597PubMedCrossRefGoogle Scholar
  45. 45.
    van den Brand MW, Pouwels S, Samson MM, van Staa TP, Thio B, Cooper C, Leufkens HG, Egberts AC, Verhaar HJ, de Vries F (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20:1705–1713PubMedCrossRefGoogle Scholar
  46. 46.
    Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F (2010) Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47:604–609PubMedCrossRefGoogle Scholar
  47. 47.
    Guo Z, Wills P, Viitanen M, Fastbom J, Winblad B (1998) Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 year old: a community-based prospective study. Am J Epidemiol 148:887–892PubMedCrossRefGoogle Scholar
  48. 48.
    Jacqmin-Gadda H, Fourrier A, Commenges D, Dartigues JF (1998) Risk factors for fractures in the elderly. Epidemiology 9:417–423PubMedCrossRefGoogle Scholar
  49. 49.
    Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A, Hanlon JT, Nevitt MC, Whooley MA, Study of Osteoporotic Fractures Research Group (2003) Central nervous system active medications and risk for fractures in older women. Arch Intern Med 163:949–957PubMedCrossRefGoogle Scholar
  50. 50.
    Lewis CE, Ewing SK, Taylor BC, Shikany JM, Fink HA, Ensrud KE, Barrett-Connor E, Cummings SR, Orwoll E, Osteoporotic Fractures in Men (MrOS) Study Research Group (2007) Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 22:211–219PubMedCrossRefGoogle Scholar
  51. 51.
    Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D, Canadian Multicentre Osteoporosis Study Research Group (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188–194PubMedCrossRefGoogle Scholar
  52. 52.
    Spector W, Shaffer T, Potter DE, Correa-de-Araujo R, Rhona Limcangco M (2007) Risk factors associated with the occurrence of fractures in U.S. nursing homes: resident and facility characteristics and prescription medications. J Am Geriatr Soc 55:327–333PubMedCrossRefGoogle Scholar
  53. 53.
    Cooper C, Jakob F, Chinn C, Martin-Mola E, Fardellone P, Adami S, Thalassinos NC, Melo-Gomes J, Torgerson D, Gibson A, Marin F (2008) Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int 19:493–501PubMedCrossRefGoogle Scholar
  54. 54.
    Spangler L, Scholes D, Brunner RL, Robbins J, Reed SD, Newton KM, Melville JL, Lacroix AZ (2008) Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med 23:567–574PubMedCrossRefGoogle Scholar
  55. 55.
    Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH (2008) Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 28:411–417PubMedCrossRefGoogle Scholar
  56. 56.
    Nurminen J, Puustinen J, Piirtola M, Vahlberg T, Kivelä SL (2010) Psychotropic drugs and the risk of fractures in old age: a prospective population-based study. BMC Publ Health 10:396CrossRefGoogle Scholar
  57. 57.
    Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S (2011) Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 183:E411–E419PubMedCrossRefGoogle Scholar
  58. 58.
    Diem SJ, Blackwell TL, Stone KL, Cauley JA, Hillier TA, Haney EM, Ensrud KE, Study of Osteoporotic Fractures Research Group (2011) Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 88:476–484PubMedCrossRefGoogle Scholar
  59. 59.
    Gagne JJ, Patrick AR, Mogun H, Solomon DH (2011) Antidepressants and fracture risk in older adults: a comparative safety analysis. Clin Pharmacol Ther 89:880–887PubMedCrossRefGoogle Scholar
  60. 60.
    Ducy P, Karsenty G (2010) The two faces of serotonin in bone biology. J Cell Biol 191:7–13PubMedCrossRefGoogle Scholar
  61. 61.
    Diem SJ, Blackwell TL, Stone KL, Yaffe K, Cauley JA, Whooley MA, Ensrud KE, Study of Osteoporotic Fractures (2007) Depressive symptoms and rates of bone loss at the hip in older women. J Am Geriatr Soc 55:824–831PubMedCrossRefGoogle Scholar
  62. 62.
    Eskandari F, Martinez PE, Torvik S, Phillips TM, Sternberg EM, Mistry S, Ronsaville D, Wesley R, Toomey C, Sebring NG, Reynolds JC, Blackman MR, Calis KA, Gold PW, Cizza G, Premenopausal, Osteoporosis Women, Alendronate, Depression (POWER) Study Group (2007) Low bone mass in premenopausal women with depression. Arch Intern Med 167:2329–2336PubMedCrossRefGoogle Scholar
  63. 63.
    Jacka FN, Pasco JA, Henry MJ, Kotowicz MA, Dodd S, Nicholson GC, Berk M (2005) Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study. Menopause 12:88–91PubMedCrossRefGoogle Scholar
  64. 64.
    Mezuk B, Eaton WW, Golden SH, Wand G, Lee HB (2008) Depression, antidepressants, and bone mineral density in a population-based cohort. J Gerontol A Biol Sci Med Sci 63:1410–1415PubMedCrossRefGoogle Scholar
  65. 65.
    Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E, Chrousos G, Gold P (1996) Bone mineral density in women with depression. N Engl J Med 335:1176–1181PubMedCrossRefGoogle Scholar
  66. 66.
    Robbins J, Hirsch C, Whitmer R, Cauley J, Harris T (2001) The association of bone mineral density and depression in an older population. J Am Geriatr Soc 49:732–736PubMedCrossRefGoogle Scholar
  67. 67.
    Mussolino ME (2005) Depression and hip fracture risk: the NHANES I epidemiologic follow-up study. Public Health Rep 120:71–75PubMedGoogle Scholar
  68. 68.
    Coelho R, Silva C, Maia A, Prata J, Barros H (1999) Bone mineral density and depression: a community study in women. J Psychosom Res 46:29–35PubMedCrossRefGoogle Scholar
  69. 69.
    Yazici KM, Akinci A, Sütçü A, Ozçakar L (2003) Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res 117:271–275PubMedCrossRefGoogle Scholar
  70. 70.
    Whooley MA, Kip KE, Cauley JA, Ensrud KE, Nevitt MC, Browner WS (1999) Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:484–490PubMedCrossRefGoogle Scholar
  71. 71.
    Whooley MA, Cauley JA, Zmuda JM, Haney EM, Glynn NW (2004) Depressive symptoms and bone mineral density in older men. J Geriatr Psychiatry Neurol 17:88–92PubMedCrossRefGoogle Scholar
  72. 72.
    Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V (2007) The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease—A cross sectional study. Respir Med 101:177–185PubMedCrossRefGoogle Scholar
  73. 73.
    Vrieze A, de Greef MH, Wijkstra PJ, Wempe JB (2007) Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int 18:1197–1202PubMedCrossRefGoogle Scholar
  74. 74.
    van Manen JG, Bindels PJE, Dekker FW, IJzermans CJ, van der Zee JS, Schadé E (2002) Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 57:412–416PubMedCrossRefGoogle Scholar
  75. 75.
    Uretmen S, Gol M, Cimrin D, Irmak E (2005) Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 123:67–71PubMedCrossRefGoogle Scholar
  76. 76.
    Bianchi G, Marchesini G, Nicolino F, Graziani R, Sgarbi D, Loguercio C, Abbiati R, Zoli M (2005) Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis 37:593–600PubMedCrossRefGoogle Scholar
  77. 77.
    George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, Bhatia SJ, Shah S, Menon PS, Shah N (2009) Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 15:3516–3522PubMedCrossRefGoogle Scholar
  78. 78.
    Strotmeyer ES, Cauley JA (2007) Diabetes mellitus, bone mineral density, and fracture risk. Curr Opin Endocrinol Diabetes Obes 14:429–435PubMedCrossRefGoogle Scholar
  79. 79.
    Talbot F, Nouwen A (2000) A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 23:1556–1562PubMedCrossRefGoogle Scholar
  80. 80.
    Campayo A, de Jonge P, Roy JF, Saz P (2010) Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry 167:580–588PubMedCrossRefGoogle Scholar
  81. 81.
    Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRefGoogle Scholar
  82. 82.
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  • V. Rabenda
    • 1
    Email author
  • D. Nicolet
    • 1
  • C. Beaudart
    • 1
  • O. Bruyère
    • 1
  • J.-Y. Reginster
    • 1
  1. 1.Department of Public Health, Epidemiology and Health EconomicsUniversity of LiègeLiègeBelgium

Personalised recommendations